P2Y12 Inhibitors: Pharmacologic Mechanism and Clinical Relevance [PDF]
Cardiovascular & Hematological Agents in Medicinal Chemistry, 2013 Platelets play a critical role in the pathogenesis of atherothrombotic processes and inhibition of platelet aggregation by antiplatelet therapy is essential and really important in the acute coronary syndromes or in the setting of percutaneous coronary intervention.
Secco GG +9 more
core +6 more sources
P2Y12-inhibitor monotherapy after coronary stenting: are all P2Y12-inhibitors equal? [PDF]
, 2022 Introduction: P2Y12-inhibitor monotherapy following 1–3 months of dual antiplatelet therapy (DAPT) reduces (major) bleeding without an apparent increase in ischemic events and has therefore emerged as an alternative to 6–12 months of DAPT following ...
Küçük, I. Tarik +10 more
core +3 more sources
P2Y12 inhibitors for the neurointerventionalist
Interventional Neuroradiology, 2021 The use of antiplatelets is widespread in clinical practice. However, for neurointerventional procedures, protocols for antiplatelet use are scarce and practice varies between individuals and institutions. This is further complicated by the quantity of antiplatelet agents which differ in route of administration, dosage, onset of action, efficacy and ...
Borchert, Robin J +11 more
openaire +3 more sources
P2Y12 inhibitor monotherapy in patients undergoing percutaneous coronary intervention. [PDF]
, 2022 For 20 years, dual antiplatelet therapy (DAPT), consisting of the combination of aspirin and a platelet P2Y12 receptor inhibitor, has been the gold standard of antithrombotic pharmacology after percutaneous coronary intervention (PCI).
Bhatt, Deepak +42 more
core +1 more source
P2Y12 blocker monotherapy after percutaneous coronary intervention [PDF]
, 2021 For secondary prevention of coronary artery disease (CAD) antiplatelet therapy is essential. For patients undergoing a percutaneous coronary intervention (PCI) temporary dual antiplatelet platelet therapy (DAPT: aspirin combined with a P2Y12 blocker) is ...
Verheugt, F. W. A. +5 more
core +1 more source
The histograms for distribution of P2Y12 reaction unit (PRU) and percent inhibition measured by VerifyNow P2Y12 assay. [PDF]
, 2023 The histograms for distribution of P2Y12 reaction unit (PRU) and percent inhibition measured by VerifyNow P2Y12 assay.
Seung Bin Kim (16425925) +3 more
core +1 more source
Pengaruh Polimorfisme P2Y12 Pada Penggunaan Antiplatelet Terhadap Kejadian Stroke Berulang [PDF]
, 2023 Stroke merupakan keadaan defisit neurologik secara fokal dan global. Salah satu pengobatan yang digunakan adalah antiplatelet seperti clopidogrel yang dapat menghambat pembentukan trombus yang bisa menurunkan angka kematian. Dalam perkembangan pengobatan,
Raising, Rahmawati +1 more
core +1 more source
P2Y12 Inhibitor or Aspirin Monotherapy for Secondary Prevention of Coronary Events [PDF]
, 2023 BACKGROUND Aspirin is the only antiplatelet agent with a Class I recommendation for long-term prevention of cardiovascular events in patients with coronary artery disease (CAD).
Anna Franzone +50 more
core +1 more source
Challenge in Predicting Persistence to P2Y12 Inhibitors: A Perspective From the ARTEMIS Trial
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2023 Background Premature discontinuation of P2Y12 inhibitor therapy has been associated with adverse cardiac events, which might be preventable by improving medication persistence. Current risk models have limited ability to predict patients at risk of P2Y12
Jennifer A. Rymer +5 more
doaj +1 more source
P2Y12 receptor in platelet activation
Platelets, 2011 ADP plays an important role in hemostasis and thrombosis. The P2Y12 receptor, activated by ADP, plays a central role in platelet activation and thrombus formation. Thus, the P2Y12 receptor has been an effective target for antithrombotic drugs.
Soochong, Kim, Satya P, Kunapuli
openaire +2 more sources